155 related articles for article (PubMed ID: 34870794)
1. An open-label, single-arm, multi-center, phase II clinical trial of single-dose [
Inaki A; Shiga T; Tsushima Y; Jinguji M; Wakabayashi H; Kayano D; Akatani N; Yamase T; Kunita Y; Watanabe S; Hiromasa T; Mori H; Hirata K; Watanabe S; Higuchi T; Tomonaga H; Kinuya S
Ann Nucl Med; 2022 Mar; 36(3):267-278. PubMed ID: 34870794
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of High-Specific-Activity
Pryma DA; Chin BB; Noto RB; Dillon JS; Perkins S; Solnes L; Kostakoglu L; Serafini AN; Pampaloni MH; Jensen J; Armor T; Lin T; White T; Stambler N; Apfel S; DiPippo VA; Mahmood S; Wong V; Jimenez C
J Nucl Med; 2019 May; 60(5):623-630. PubMed ID: 30291194
[TBL] [Abstract][Full Text] [Related]
3. A phase I clinical trial for [
Wakabayashi H; Inaki A; Yoshimura K; Murayama T; Imai Y; Higuchi T; Jinguji M; Shiga T; Kinuya S
Sci Rep; 2019 May; 9(1):7625. PubMed ID: 31110198
[TBL] [Abstract][Full Text] [Related]
4. Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma.
Jimenez C; Chin BB; Noto RB; Dillon JS; Solnes L; Stambler N; DiPippo VA; Pryma DA
Endocr Relat Cancer; 2023 Feb; 30(2):. PubMed ID: 36472300
[TBL] [Abstract][Full Text] [Related]
5. A phase I clinical trial for [
Inaki A; Yoshimura K; Murayama T; Imai Y; Kuribayashi Y; Higuchi T; Jinguji M; Shiga T; Kinuya S
J Med Invest; 2017; 64(3.4):205-209. PubMed ID: 28954983
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma.
Noto RB; Pryma DA; Jensen J; Lin T; Stambler N; Strack T; Wong V; Goldsmith SJ
J Clin Endocrinol Metab; 2018 Jan; 103(1):213-220. PubMed ID: 29099942
[TBL] [Abstract][Full Text] [Related]
7. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
8. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
Gonias S; Goldsby R; Matthay KK; Hawkins R; Price D; Huberty J; Damon L; Linker C; Sznewajs A; Shiboski S; Fitzgerald P
J Clin Oncol; 2009 Sep; 27(25):4162-8. PubMed ID: 19636009
[TBL] [Abstract][Full Text] [Related]
10. Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid.
Coleman RE; Stubbs JB; Barrett JA; de la Guardia M; Lafrance N; Babich JW
Cancer Biother Radiopharm; 2009 Aug; 24(4):469-75. PubMed ID: 19694582
[TBL] [Abstract][Full Text] [Related]
11. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.
Gedik GK; Hoefnagel CA; Bais E; Olmos RA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):725-33. PubMed ID: 18071700
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.
Thorpe MP; Kane A; Zhu J; Morse MA; Wong T; Borges-Neto S
J Clin Endocrinol Metab; 2020 Mar; 105(3):e494-501. PubMed ID: 31614368
[TBL] [Abstract][Full Text] [Related]
13. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
14. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
Troncone L; Rufini V
Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
[TBL] [Abstract][Full Text] [Related]
15. I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma.
Zhang X; Wakabayashi H; Kayano D; Inaki A; Kinuya S
Nuklearmedizin; 2022 Jun; 61(3):231-239. PubMed ID: 35668668
[TBL] [Abstract][Full Text] [Related]
16. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
17. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma.
Fukuoka M; Taki J; Mochizuki T; Kinuya S
Clin Nucl Med; 2011 Jan; 36(1):1-7. PubMed ID: 21157198
[TBL] [Abstract][Full Text] [Related]
18. Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre.
Rutherford MA; Rankin AJ; Yates TM; Mark PB; Perry CG; Reed NS; Freel EM
QJM; 2015 May; 108(5):361-8. PubMed ID: 25267727
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of
Maric I; Weber M; Prochnow A; Schmitz J; Unger N; Schaarschmidt BM; Poeppel TD; Rischpler C; Bockisch A; Herrmann K; Jentzen W; Fendler WP
J Nucl Med; 2023 Jun; 64(6):885-891. PubMed ID: 36732054
[TBL] [Abstract][Full Text] [Related]
20. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG.
Fishbein L; Bonner L; Torigian DA; Nathanson KL; Cohen DL; Pryma D; Cengel KA
Horm Metab Res; 2012 May; 44(5):405-10. PubMed ID: 22566196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
